2013 SEP 16 (NewsRx) -- By a News Reporter-Staff News Editor at AIDS Weekly -- A new study on Biotechnology is now available. According to news reporting out of Bethesda, Maryland, by NewsRx editors, research stated, "DNA vaccines have been very poorly immunogenic in humans but have been an effective priming modality in prime-boost regimens. Methods to increase the immunogenicity of DNA vaccines are needed."
Our news journalists obtained a quote from the research from the National Institute of Allergy and Infectious Diseases (NIAID), "HIV Vaccine Trials Network (HVTN) studies 070 and 080 were multicenter, randomized, clinical trials. The human immunodeficiency virus type 1 (HIV-1) PENNVAX®-B DNA vaccine (PV) is a mixture of 3 expression plasmids encoding HIV-1 Clade B Env, Gag, and Pol. The interleukin 12 (IL-12) DNA plasmid expresses human IL-12 proteins p35 and p40. Study subjects were healthy HIV-1-uninfected adults 18-50 years old. Four intramuscular vaccinations were given in HVTN 070, and 3 intramuscular vaccinations were followed by electroporation in HVTN 080. Cellular immune responses were measured by intracellular cytokine staining after stimulation with HIV-1 peptide pools. Vaccination was safe and well tolerated. Administration of PV plus IL-12 with electroporation had a significant dose-sparing effect and provided immunogenicity superior to that observed in the trial without electroporation, despite fewer vaccinations. A total of 71.4% of individuals vaccinated with PV plus IL-12 plasmid with electroporation developed either a CD4(+) or CD8(+) T-cell response after the second vaccination, and 88.9% developed a CD4(+) or CD8(+) T-cell response after the third vaccination. Use of electroporation after PV administration provided superior immunogenicity than delivery without electroporation."
According to the news editors, the research concluded: "This study illustrates the power of combined DNA approaches to generate impressive immune responses in humans."
For more information on this research see: Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery. Journal of Infectious Diseases, 2013;208(5):818-829. Journal of Infectious Diseases can be contacted at: Oxford Univ Press Inc, Journals Dept, 2001 Evans Rd, Cary, NC 27513, USA. (Oxford University Press - www.oup.com/; Journal of Infectious Diseases - jid.oxfordjournals.org)
Our news journalists report that additional information may be obtained by contacting S.A. Kalams, NIAID, Bethesda, MD 20892, United States. Additional authors for this research include S.D. Parker, M. Elizaga, B. Metch, S. Edupuganti, J. Hural, S. De Rosa, D.K. Carter, K. Rybczyk, I. Frank, J. Fuchs, B. Koblin, D.H. Kim, P. Joseph, M.C. Keefer, L.R. Baden, J. Eldridge, J. Boyer, A. Sherwat and M. Cardinali (see also Biotechnology).
Keywords for this news article include: Biotechnology, Bethesda, Maryland, HIV/AIDS, Peptides, Proteins, Virology, Cytokines, Viral DNA, RNA Viruses, Vaccination, DNA Research, DNA Vaccines, Immunization, Retroviridae, United States, HIV Infections, Interleukin-12, Synthetic Vaccines, Vertebrate Viruses, Biological Products, Primate Lentiviruses
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2013, NewsRx LLC